A5050963621- Inflammatory Bowel Disease
- Immune Cell Function and Interaction
- Microscopic Colitis
- IL-33, ST2, and ILC Pathways
- Endoplasmic Reticulum Stress and Disease
- Liver Disease Diagnosis and Treatment
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- T-cell and B-cell Immunology
- Autophagy in Disease and Therapy
- Gut microbiota and health
- Immunodeficiency and Autoimmune Disorders
- Hepatitis C virus research
- Inflammasome and immune disorders
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- Whipple's Disease and Interleukins
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
- Pancreatitis Pathology and Treatment
- Diabetes and associated disorders
- Immune Response and Inflammation
- Autoimmune and Inflammatory Disorders
- Clostridium difficile and Clostridium perfringens research
- Immune cells in cancer
University of Cambridge
2016-2025
Addenbrooke's Hospital
2015-2025
Cambridge University Hospitals NHS Foundation Trust
2015-2025
MRC Epidemiology Unit
2021-2024
Massachusetts Institute of Technology
2023
ETH Zurich
2023
Université Côte d'Azur
2018
Brigham and Women's Hospital
2004-2017
Harvard University
2001-2017
University of Amsterdam
2017
Abstract Adipocytokines are mainly adipocyte-derived cytokines regulating metabolism and as such key regulators of insulin resistance. Some adipocytokines adiponectin leptin affect immune inflammatory functions. Visfatin (pre-B cell colony-enhancing factor) has recently been identified a new adipocytokine affecting resistance by binding to the receptor. In this study, we show that recombinant visfatin activates human leukocytes induces cytokine production. CD14+ monocytes, production IL-1β,...
Abstract The increased incidence of inflammatory bowel disease (IBD) has become a global phenomenon that could be related to adoption Western life-style. Westernization dietary habits is partly characterized by enrichment with the ω-6 polyunsaturated fatty acid (PUFA) arachidonic (AA), which entails risk for developing IBD. Glutathione peroxidase 4 (GPX4) protects against lipid peroxidation (LPO) and cell death termed ferroptosis. We report small intestinal epithelial cells (IECs) in Crohn’s...
The GEMINI long-term safety [LTS] study is a continuing phase 3 trial investigating the and efficacy of vedolizumab, an α4β7 integrin antagonist for ulcerative colitis [UC] Crohn’s disease. We provide interim analysis in patients with UC. Patients from C13004 1 studies cohort vedolizumab-naïve received open-label vedolizumab every 4 weeks. Interim data were collected May 22, 2009 to June 27, 2013. Clinical response remission, evaluated using partial Mayo scores, health-related quality life...
Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial an ongoing open-label study investigating the of vedolizumab. We present interim exploratory analyses efficacy in patients with Patients from C13004, 2 3 studies vedolizumab-naïve could enrol LTS received vedolizumab every 4 weeks. Data were collected May 22, 2009 to June 27, 2013. Outcomes clinical response remission, defined by Harvey-Bradshaw...
IgG antibodies cause inflammation and organ damage in autoimmune diseases such as systemic lupus erythematosus (SLE). We investigated the metabolic profile of macrophages isolated from inflamed tissues immune complex (IC)-associated diseases, including SLE rheumatoid arthritis, following Fcγ receptor cross-linking. found that human mouse undergo a switch to glycolysis response IC stimulation, mirroring macrophage changes tissue vivo. This reprogramming was required generate number...